輸血安全性提昇非常仰賴輸血醫學技術的持續進步，減除白血球血品的問世便是輸血安全的重要 進展之一。研究顯示使用減除白血球之諸多血品能直接改善特定輸血不良反應的發生率及嚴重性，其中 實證醫學有顯著效果的包含：降低巨細胞病毒(cytomegalovirus，CMV)感染風險、減少非溶血性發熱性輸 血反應及預防血小板輸注無效；此外，輸血治療不良反應減少也同時反應醫療照護費用降低及病人照護 品質提昇。臨床輸血治療使用減除白血球血品是一個無風險且對病人有益的治療選擇。

The increasing safety of blood transfusion primarily depends on persistent improvement of transfusion medicine technology, and the development of leukocyte reduction techniques for blood components is one of the major progresses. Many studies showed the usage of various leukocyte-reduced blood components can directly reduce in the frequency and severity of some transfusion reactions. Some of them are strongly evidence-based, including reduced cytomegalovirus transfusion-transmission risk, reduction of non-hemolytic febrile transfusion reactions, and reduced incidence of platelet transfusion refractoriness. Reduction of those transfusion reactions can also lead to cost-saving and quality improvement of healthcare. For clinical transfusion, leukocyte-reduced blood components are risk-free and patient-benefit treatment choices.